Idenix Pharmaceuticals Reports Q1 Financial Results

Biopharmaceutical company Idenix reported total revenues of $4.0 million for the first quarter of 2011.

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases,  announced yesterday unaudited financial results for the first quarter of 2011. At March 31, 2011, Idenix's cash and cash equivalents totaled $31.4 million.

For the first quarter ended March 31, 2011, Idenix reported total revenues of $4.0 million, compared to total revenues of $2.7 million in the first quarter of 2010. The company reported a net loss of $8.2 million, or a loss of <